The 6-minute walk test: normal values for children of 4-11 years of age

被引:201
作者
Lammers, A. E. [1 ]
Hislop, A. A. [2 ]
Flynn, Y.
Haworth, S. G. [2 ]
机构
[1] Great Ormond St Hosp Sick Children, Dept Paediat Cardiol, London WC1N 3JH, England
[2] UCL, Inst Child Hlth, London, England
关键词
D O I
10.1136/adc.2007.123653
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: The 6-minute walk test (6MWT) is an established measure of exercise capacity in adults and children with chronic cardiac or respiratory disease. Despite its widespread use, there are no normal values for healthy children under 12 years of age. We aimed to provide normal values for children between 4 and 11 years. Methods: Healthy children were recruited prospectively from two UK primary schools and also children visiting Great Ormond Street Hospital. 328 children (54% male) aged 4 to 11 years were included in the study. Main outcome measures were the distance walked in 6 minutes, and oxygen saturation and heart rate during the 6 minutes and during a 3-minute recovery period. Results: Mean oxygen saturation at baseline and during the 6MWT was 97-99%. Heart rate increased from 102 +/- 19 bpm at baseline to a maximum of 136 +/- 12 bpm. Overall, the mean distance walked in 6 minutes was 470 +/- 59 m. Distance walked correlated with age (r=0.64, p< 0.0001), weight (r=0.51, p< 0.0001) and height (r=0.65, p, 0.0001) with no significant difference between boys and girls. The distance walked increased significantly year on year from 4 to 7 years (4 years 383 +/- 41 m; 5 years 420 +/- 39 m, 6 years 463 +/- 40 m; 7 years 488 +/- 35 m; p<0.05 between each); further modest increases were observed beyond 7 years of age. Conclusions: Performing a 6MWT is feasible and practical in young children. This study provides data on normal children against which the performance of sick children and the response to therapeutic intervention can be judged.
引用
收藏
页码:464 / 468
页数:5
相关论文
共 30 条
  • [11] Grummer-Strawn, 2000, ADV DATA, V8, P1
  • [12] Gulmans VAM, 1996, PEDIATR PULM, V22, P85, DOI 10.1002/(SICI)1099-0496(199608)22:2<85::AID-PPUL1>3.0.CO
  • [13] 2-I
  • [14] Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
    Hoeper, MM
    Markevych, I
    Spiekerkoetter, E
    Welte, T
    Niedermeyer, J
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (05) : 858 - 863
  • [15] End points and clinical trial designs in pulmonary arterial hypertension - Clinical and regulatory perspectives
    Hoeper, MM
    Oudiz, RJ
    Peacock, A
    Tapson, VF
    Haworth, SG
    Frost, AE
    Torbicki, A
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) : 48S - 55S
  • [16] Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension - Twelve-month clinical trial of a single-drug, open-label, pilot study
    Humpl, T
    Reyes, JT
    Holtby, H
    Stephens, D
    Adatia, I
    [J]. CIRCULATION, 2005, 111 (24) : 3274 - 3280
  • [17] Reliability and intensity of the six-minute walk test in healthy elderly subjects
    Kervio, G
    Carre, F
    Ville, NS
    [J]. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2003, 35 (01) : 169 - 174
  • [18] Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease
    Kessler, R
    Faller, M
    Fourgaut, G
    Mennecier, B
    Weitzenblum, E
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (01) : 158 - 164
  • [19] REPRODUCIBILITY OF WALKING TEST-RESULTS IN CHRONIC OBSTRUCTIVE AIRWAYS DISEASE
    KNOX, AJ
    MORRISON, JFJ
    MUERS, MF
    [J]. THORAX, 1988, 43 (05) : 388 - 392
  • [20] Epoprostenol treatment in children with severe pulmonary hypertension
    Lammers, Astrid E.
    Hislop, Alison A.
    Flynn, Yvette
    Haworth, Sheila G.
    [J]. HEART, 2007, 93 (06) : 739 - 743